Unlock instant, AI-driven research and patent intelligence for your innovation.

Agent for prevention and/or treatment of systemic lupus erythematosus

A lupus erythematosus, systemic technology, applied in the directions of non-central analgesics, anti-inflammatory agents, allergic diseases, etc., can solve the problem of unknown effect of combined use of adrenal corticosteroids and IL-1β inhibitors, and achieve excellent inhibitory effect , the effect of small side effects

Inactive Publication Date: 2010-01-20
KOWA CO LTD
View PDF1 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0026] However, the combined effect of adrenocorticosteroids and IL-1β inhibitors on SLE is still unknown

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Agent for prevention and/or treatment of systemic lupus erythematosus
  • Agent for prevention and/or treatment of systemic lupus erythematosus
  • Agent for prevention and/or treatment of systemic lupus erythematosus

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0068] Evaluation of 2-benzyl-5-(4-chlorophenyl)-6-[4-(methylthio)phenyl using NZB×NZW (NZB / W)F1 mice known as a natural onset model of SLE ]-Suppressive effect of combined administration of 2H-pyridazin-3-one (hereinafter referred to as drug A) and prednisolone (hereinafter referred to as drug B) and single administration of the two drugs on expression of disease-related genes in kidney .

[0069] As test animals, female NZB / WF1 mice (Nippon SLC Co., Ltd.) were used.

[0070] The body weight of 20-week-old NZB / WF1 mice was measured, and using this as an index, block randomization was performed according to univariate, thereby dividing into homogeneous groups.

[0071] Drug administration was performed from the second day of grouping until 10 weeks later. For the drug A alone administration group, 30 mg / kg was orally administered twice in the morning (9:00-11:00) and in the afternoon (15:30-17:30). In addition, to the drug B alone administration group, 3 mg / kg was orally ad...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

Disclosed is an agent for prevention and / or treatment of systemic lupus erythematosus which is obtained by combining 2-benzyl-5-(4-chlorophenyl)-6-¢4-(methylthio)phenyl!-2H- pyridazin-3-one or a solvate thereof with a adrenocortical steroid. This pharmaceutical agent is orally administrable and has few side effects. This pharmaceutical agent has an excellent effect of suppressing symptoms associated with SLE, and is thus useful for prevention and treatment of SLE.

Description

technical field [0001] The present invention relates to a preventive and / or therapeutic agent for systemic lupus erythematosus. Background technique [0002] Systemic lupus erythematosus (Systemic Lupus Erythematosus: SLE) is an autoimmune disease characterized by systemic inflammatory lesions caused by tissue deposition of DNA-anti-DNA and other immune complexes. It has the following characteristics: Symptoms are relieved by treatment, but most of them experience a repeated and long process of remission and exacerbation. The incidence rate of SLE in the general population is estimated to be 10-100 per 100,000 people, and the incidence rate rises to 2-4% in the case of first-degree relatives with SLE patients. In other words, the incidence rate rises to 25%. Therefore, it can be considered that SEL is a disease with a large genetic factor. In addition, it is known that although the male-to-female ratio of the incidence rate is 1:9, if the age group that can give birth is ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/573A61K31/50A61P37/02A61P43/00C07D237/06
CPCA61K31/50C07D237/06A61K31/573A61P29/00A61P37/00A61P37/02A61P43/00
Inventor 天竺桂裕一朗
Owner KOWA CO LTD